Chiome Bioscience (4583.T) traded down -1.1 % during a 24 hours period ending at 02:19 AM Central Europe on Tuesday 27th. One Chiome Bioscience stock can currently be bought for about JPY 92 on popular exchanges. Current supply of Chiome Bioscience stocks is 78.9 mn. Chiome Bioscience has a current market capitalization of JPY 7.1 bn and approximately JPY 36.7 mn worth of Chiome Bioscience was traded on exchanges in the last 24 hours. Since last month end, Chiome Bioscience has traded -13.46 % down. Simple moving average of last 200 days is at JPY 93.74. The highest price of past 52 weeks was recorded at JPY 136 on 11/11/2025. 52 weeks low was at JPY 65 on 06/25/2026.

Here is how related stocks have performed in the past 24 hours:

  • Tokyo Kisen (9193.T) traded down -0.82 % and now trades at JPY 836. Tokyo Kisen has a market capitalisation of JPY 8.4 bn. Current price/earnings ratio for Tokyo Kisen is 1.62.

  • Jtp (2488.T) traded down -1.9 % and now trades at JPY 1,504. Jtp has a market capitalisation of JPY 8.4 bn. Current price/earnings ratio for Jtp is 23.58.

  • Papyless (3641.T) traded up 0.2 % and now trades at JPY 975. Papyless has a market capitalisation of JPY 8.5 bn.

  • Nankai Chemical (4040.T) traded down -2.41 % and now trades at JPY 4,455. Current market capitalisation for Nankai Chemical is JPY 8.5 bn.

  • Secuavail (3042.T) traded up 0.27 % and now trades at JPY 1,626. Secuavail has a market capitalisation of JPY 8.5 bn. Secuavail has a current price to earnings ratio of 391.45.

About Chiome Bioscience

Chiome Bioscience Inc. is a health care company operating in the life sciences tools & services sector with its main operations based in Tokyo, Japan. The company specializes in drug discovery platform technology worldwide, with its proprietary ADLib System monoclonal antibody generating technology being the focus of its drug discovery and development efforts. Through Drug Discovery and Development Business and Drug Discovery Support Business segments, Chiome Bioscience Inc. works to advance various antibody drugs in-house or in collaboration with partners up to late pre-clinical stage, ultimately preparing data packages for IND or early clinical stage in diverse therapeutic areas. The Drug Discovery Support Business segment offers fee-for-service to pharmaceutical and diagnostics companies; and academia, providing support for research works by generating a monoclonal antibody using its proprietary platform, expressing, culturing, and purifying proteins including antigens and antibodies. Chiome Bioscience Inc.’s product pipeline includes LIV-1205, a humanized anti-DLK-1 antibody to treat liver cancer and intractable cancers; LIV-2008/LIV-2008b, a humanized anti-TROP-2 antibody for the treatment of TROP-2; and BMAA, a humanized anti-semphoring 3A antibody for treating semaphorin 3A. The company was founded in 2005 and is currently headquartered in Tokyo, Japan. The website for Chiome Bioscience Inc. is www.chiome.co.jp , and the company’s IPO took place on the Tokyo Stock Exchange in December 2011.